Study #2021-0201
Minimal Residual Disease Guided Maintenance Therapy with Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Belantamab mafodotin, Lenalidomide
Description
To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloma Multiple
Study phase:
Phase II
Physician name:
Qaiser Bashir
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-364-0962
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.